ISTA Pharmaceuticals Announces Phase 3 Results for PROLENSA(TM) Eye Drops for Treatment of Pain and Inflammation After Cataract Surgery
October 18, 2011
Last week, ISTA Pharmaceuticals announced statistically significant results from the company’s Phase 3 clinical program for PROLENSA(TM) (bromfenac ophthalmic solution).
PROLENSA is a low concentration of bromfenac in a modified ophthalmic solution developed to treat pain and inflammation associated with cataract surgery. In both Phase 3 studies, PROLENSA was statistically significantly better than placebo and met the primary efficacy endpoint of absence of ocular inflammation 14 days following surgery and the secondary efficacy endpoint of elimination of ocular pain one day post-surgery. There were no serious drug-related ocular or systemic adverse events, and PROLENSA’s safety profile was found to be consistent with ISTA’s currently marketed topical non-steroidal anti-inflammatory (NSAID) compound, BROMDAY(TM) (bromfenac ophthalmic solution) 0.09%.
Click here for the full release.
Jump down to form below to submit your own comments